Lakefront Biotherapeutics (LKFT) Assets Average (2015 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Assets Average of $4.0 billion for Q1 2026, down 8.51% year-over-year from $4.3 billion in Q1 2025, and down 1.95% quarter-over-quarter from $4.0 billion in Q4 2025.
Powered by 
Analysis
Lakefront Biotherapeutics (LKFT) Assets Average (2015 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Assets Average for 11 consecutive years, with $4.0 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 8.51% year-over-year to $4.0 billion; the TTM figure through Mar 2026 stood at $4.0 billion (down 8.51% YoY), while the FY2025 annual figure was $4.2 billion, down 7.94% from the prior year.
- Assets Average fell to $4.0 billion in Q1 2026 per LKFT's latest filing, from $4.0 billion in the prior quarter.
- Across five years, Assets Average topped out at $5.8 billion in Q1 2022 and bottomed at $4.0 billion in Q1 2026.
- Historically, Assets Average has averaged $4.6 billion across 5 years, with a median of $4.4 billion in 2025.
- Annual changes were most pronounced in 2023 — Assets Average decreased 15.97% — and 2024, when it slipped 3.83%.
- Lakefront Biotherapeutics' Assets Average stood at $5.8 billion in 2022, then slipped by 18.27% to $4.8 billion in 2023, then declined by 5.59% to $4.5 billion in 2024, then dropped by 10.34% to $4.0 billion in 2025, then slipped by 1.95% to $4.0 billion in 2026.
- Business Quant data shows LKFT's Assets Average at $4.0 billion in Q1 2026, $4.0 billion in Q4 2025, and $4.2 billion in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.22 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 3.29 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.86 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Lakefront Biotherapeutics | 1.88 Bn | 1.88 Bn | 3.51 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 3.96 Bn |
| Dec 31, 2025 | 4.04 Bn |
| Sep 30, 2025 | 4.21 Bn |
| Jun 30, 2025 | 4.28 Bn |
| Mar 31, 2025 | 4.33 Bn |
| Dec 31, 2024 | 4.50 Bn |
| Mar 31, 2024 | 4.71 Bn |
| Dec 31, 2023 | 4.77 Bn |
| Mar 31, 2023 | 4.90 Bn |
| Mar 31, 2022 | 5.83 Bn |
| Jun 30, 2020 | 6.53 Bn |
| Mar 31, 2020 | 6.67 Bn |
| Dec 31, 2019 | 6.61 Bn |
| Sep 30, 2019 | 4.02 Bn |
| Jun 30, 2019 | 1.56 Bn |
| Mar 31, 2019 | 1.62 Bn |
| Dec 31, 2018 | 1.69 Bn |
| Sep 30, 2018 | 1.58 Bn |
| Jun 30, 2018 | 1.47 Bn |
| Mar 31, 2018 | 1.51 Bn |